{
    "clinical_study": {
        "@rank": "107524", 
        "acronym": "OAB", 
        "arm_group": [
            {
                "arm_group_label": "Solifenacin Succinate Tablets  and Estrogen capsules", 
                "arm_group_type": "Experimental", 
                "description": "Solifenacin Succinate Tablets (5mg/d) + local estrogen for 12 weeks"
            }, 
            {
                "arm_group_label": "Solifenacin Succinate Tablets", 
                "arm_group_type": "Active Comparator", 
                "description": "Solifenacin Succinate Tablets (5mg/d) for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a multi-site, randomized, opened and parallel-controlled clinical study.\n\n      The patients up to the inclusion criteria are randomly treated with Solifenacin Succinate\n      Tablets (5mg/d) or Solifenacin Succinate Tablets (5mg/d) + local estrogen for 12 weeks.\n      Before the dosing and at Week 4, 8 and 12 of the dosing, various examinations are made, and\n      various indices are evaluated."
        }, 
        "brief_title": "Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Overactive Bladder", 
            "Postmenopausal Disorder", 
            "Urination Disorders"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Urination Disorders", 
                "Urinary Bladder, Overactive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Post-menopausal women aged \u226475.\n\n          -  Signing of ICF.\n\n          -  Willing to and able to correctly complete the urination diary.\n\n          -  Complications of OAB for \u226512 weeks (including: urgent micturition, frequent urination\n             (\u22658 times in the daytime, and \u22652 times at the night) and/or urgent urinary\n             incontinence).\n\n          -  No dosing of other drugs of same kind within 14d. -\u22658 urination times (24h) in the 1d\n             urination diary.\n\n        Exclusion Criteria:\n\n          -  Clinically-significant dysuria(at the investigators' viewpoints).\n\n          -  Serious stress urinary incontinence or mixed stress/urgent urinary incontinence\n             (mainly stress one) confirmed by the investigators.\n\n          -  At the ongoing intubatton or the intermittent self-intubatton.\n\n          -  Evidence-based urinary tract infection or chronic inflammation in the recent 2 weeks\n             (e.g. interstitial cystitis), bladder calculus, past pelvic radiotherapy, and past or\n             existing pelvic malignant tumors.\n\n          -  Uncontrolled narrow-angle glaucoma, urinary/gastric retention, intestinal obstruction\n             and other medical symptoms forbidden for anti-cholinergic drugs at the investigators'\n             viewpoints.\n\n          -  Non-pharmacotherapy (including electrotherapy) or bladder training within 2 weeks\n             before the study initiation (or during the study).\n\n          -  Dosing of diuretics and drugs with the cholinergic or anti-cholinergic adverse\n             reactions\n\n          -  Known or suspicious allergy to Solifenacin Succinate, other anti-cholinergic drugs or\n             lactose.\n\n          -  Clinically-significant symptoms inapplicable for clinical study at the investigators'\n             viewpoints.\n\n          -  Participation in other clinical studies within 30d before the random grouping.\n\n          -  No completion of urination diary according to relevant instructions.\n\n          -  Potentially clinically significant abnormalities (PCSA) inapplicable for clinical\n             study at the investigators' viewpoints."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01833663", 
            "org_study_id": "XH-WXK-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Solifenacin Succinate Tablets  and Estrogen capsules", 
                    "Solifenacin Succinate Tablets"
                ], 
                "intervention_name": "Solifenacin Succinate Tablets", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Solifenacin Succinate Tablets  and Estrogen capsules", 
                "intervention_name": "Estrogen", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Estrogens", 
                "Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Overactive Bladder", 
            "Solifenacin Succinate Tablets", 
            "Estrogen"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100730"
                }, 
                "name": "Peking Union Medical College Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multi-site, Randomized, Opened and Controlled Comparison Study on the Effectiveness and Safety of Solifenacin Succinate Tablets and Solifenacin Succinate Tablets + Estrogen for Overactive Bladder in the Post-menopausal Women", 
        "overall_official": {
            "affiliation": "Peking Union Medical College Hospital", 
            "last_name": "Lan Zhu, doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Difference between the mean urination times (24h) at the end of treatment and the baseline value", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01833663"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Difference between the mean urgent micturition times (24h) and the baseline value", 
            "safety_issue": "No", 
            "time_frame": "on week 12"
        }, 
        "source": "Peking Union Medical College Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Astellas Pharma China, Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Beijing CAT Science Co., Ltd.", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Peking Union Medical College Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}